Although FLT3 inhibitors have shown high remission rates in the treatment of AML with FLT3-ITD mutations, the problems of short-lasting remissions and the emergence of drug resistance in the short term have never been resolved. The gene discussed is FLT3; the disease is acute myeloid leukemia.